Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intermittent adjuvant chemo-immunotherapy after resection of non-small cell lung cancer with multilevel mediastinal lymph node metastasis
Autore:
Suzuki, M; Kimura, H; Iwai, N; Fujisawa, T;
Indirizzi:
Chiba Univ, Sch Med, Dept Surg, Inst Pulm Canc Res,Chuo Ku, Chiba 2608677,Japan Chiba Univ Chiba Japan 2608677 ulm Canc Res,Chuo Ku, Chiba 2608677,Japan Chiba Univ, Sch Med, Div Thorac Dis, Chiba Canc Ctr,Chuo Ku, Chiba 2608677, Japan Chiba Univ Chiba Japan 2608677 ba Canc Ctr,Chuo Ku, Chiba 2608677, Japan
Titolo Testata:
ONCOLOGY REPORTS
fascicolo: 3, volume: 7, anno: 2000,
pagine: 545 - 549
SICI:
1021-335X(200005/06)7:3<545:IACARO>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVATED KILLER CELLS; MEDIATED CYTOTOXICITY; INDUCTION CHEMOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; FAS; RADIOTHERAPY; INVOLVEMENT; THERAPY; TRIAL;
Keywords:
multilevel mediastinal lymph node metastasis; chemo-immunotherapy; interleukin-2; lymphokine-activated killer cells; interferon gamma;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Suzuki, M Chiba Univ, Sch Med, Dept Surg, Inst Pulm Canc Res,Chuo Ku, 1-8-1 Inohana,Chiba 2608677, Japan Chiba Univ 1-8-1 Inohana Chiba Japan 2608677 iba 2608677, Japan
Citazione:
M. Suzuki et al., "Intermittent adjuvant chemo-immunotherapy after resection of non-small cell lung cancer with multilevel mediastinal lymph node metastasis", ONCOL REP, 7(3), 2000, pp. 545-549

Abstract

The prognosis of patients with multilevel mediastinal lymph node metastasis remains poor notwithstanding the progress in multimodal therapy in non-small cell lung cancer. We conducted a feasible study of intermittent adjuvant chemo-immunotherapy after surgery for patients with multilevel mediastinal lymph node metastasis of non-small cell lung cancer. Eleven patients withpathologically N2 or N3 lung cancer (10, adenocarcinomas; 1, squamous cellcarcinoma) were enrolled. Five completely resected cases received systemicchemo-immunotherapy and six incompletely resected cases received local chemo-immunotherapy by an indwelling catheter in the thoracic cavity. Cisplatin-based and dose-dependent anti-cancer drugs were selected on the basis of sensitivity tests. Either adoptive immunotherapy with interleukin-2 and lymphokine-activated killer eel or combination of interferon gamma and OK432 were administered after chemotherapy. This adjuvant therapy was performed every 2-3 months after surgery for 2 years. The 2-year survival rate for all cases were 72.7% and the 2-year disease-free survival were 36.4%. The 2-year survival rate for five completely resected cases and six incompletely resected cases was 80% and 66.7%, respectively. Combined intermittent chemo-immunotherapy after surgical resection of tumors may be a promising modality to improve the survival of patients with multilevel mediastinal lymph node metastasis in non-small cell lung cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 20:54:32